Background Pemetrexed is widely used for the treatment of advanced non-squamous non-small-cell lung malignancy (NSCLC). to better survival end result whereas mutation two or more metastatic sites and intra-abdominal metastasis were each associated with a poor PFS. ALK translocation showed a tendency for any positive impact on response to pemetrexed whereas metastatic lesion to liver… Continue reading Background Pemetrexed is widely used for the treatment of advanced non-squamous